Medical knowledge is growing faster than ever, as is the challenge of keeping up with this ever-growing body of information. Clinicians need a system or method to help them sort and evaluate the quality of new information before they can apply it to clinical care. Without such a system, when facing an overload of information, most of us tend to take the first or the most easily accessed information, without considering the quality of such information. As a result, the use of poor-quality information affects the quality and outcome of care we provide, and costs billions of dollars annually in problems associated with underuse, overuse, and misuse of treatments.

In an effort to sort and evaluate recently published research that is ready for clinical use, the first author (SAS) used the following 3-step methodology:

1. Searched literature for research findings suggesting readiness for clinical utilization published between July 1, 2018 and June 30, 2019.
2. Surveyed members of the American Association of Chairs of Departments of Psychiatry, the American Association of Community Psychiatrists, the American Association of Psychiatric Administrators, the North Carolina Psychiatric Association, the Group for the Advancement of Psychiatry, and many other colleagues by asking them: “Among the articles published from July 1, 2018 to June 30, 2019, which ones in your opinion have (or are likely to have or should have) affected/changed the clinical practice of psychiatry?”
3. Looked for appraisals in post-publication reviews such as NEJM Journal Watch, F1000 Prime, Evidence-Based Mental Health, commentaries in peer-reviewed journals, and other sources (see Related Resources, page 18).

We chose 12 articles based on their clinical relevance/applicability. Here in Part 1 we present brief descriptions of the 6 of top 12 papers chosen by this methodology; these studies are summarized in the Table (page 14).
The order in which they appear in this article is arbitrary. The remaining 6 studies will be reviewed in Part 2 in the February 2020 issue of Current Psychiatry.


Children and young adults are increasingly being prescribed antipsychotic medications. Studies have suggested that when these medications are used in adults and older patients, they are associated with an increased risk of death.\(^7\)\(^-\)\(^9\) Whether or not these medications are associated with an increased risk of death in children and youth has been unknown. Ray et al\(^1\) compared the risk of unexpected death among children and youths who were beginning treatment with an antipsychotic or control medications.

### Study design

- **This retrospective cohort study evaluated children and young adults age 5 to 24 who were enrolled in Medicaid in Tennessee between 1999 and 2014.**
- **New antipsychotic use at both a higher dose (>50 mg chlorpromazine equivalents) and a lower dose (≤50 mg chlorpromazine equivalents) was compared with new use of a control medication, including attention-

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ray et al(^1) (2019)</td>
<td>Large retrospective cohort study of children/young adults age 5 to 24 who received higher-dose antipsychotics (&gt;50 mg chlorpromazine equivalents; (n = 30,120)), lower-dose antipsychotics (≤50 mg chlorpromazine equivalents; (n = 28,377)), or control medications ((n = 189,361))</td>
<td>Compared with the control medication group, the incidence of death was significantly higher in the higher-dose antipsychotic group, but not in the lower-dose antipsychotic group</td>
</tr>
<tr>
<td>Daly et al(^2) (2019)</td>
<td>Double-blind, randomized study of 705 adults who received intranasal esketamine for TRD. Two hundred ninety-seven participants achieved remission or stable response and were randomized to receive continued esketamine nasal spray plus an oral antidepressant, or a placebo nasal spray plus an oral antidepressant</td>
<td>Continued esketamine nasal spray plus an oral antidepressant was associated with decreased rates of relapse compared with treatment with placebo nasal spray and an oral antidepressant</td>
</tr>
<tr>
<td>Williams et al(^3) (2018)</td>
<td>Double-blind crossover study in which 12 patients with TRD received placebo or naltrexone prior to an IV infusion of ketamine</td>
<td>Reductions in HAM-D scores among participants in the ketamine plus naltrexone group were significantly lower than those of participants in the ketamine plus placebo group</td>
</tr>
<tr>
<td>Nidich et al(^4) (2018)</td>
<td>Comparative effectiveness trial in which 203 veterans with PTSD were randomly assigned to receive TM, PE, or PTSD health education</td>
<td>Transcendental meditation was found to be significantly non-inferior to PE, with a mean change in CAPS score of -16.1 in the TM group and -11.2 in the PE group</td>
</tr>
<tr>
<td>Raskind et al(^5) (2018)</td>
<td>Double-blind controlled trial in which 304 veterans with PTSD nightmares were randomly assigned to prazosin or placebo</td>
<td>Compared with placebo, prazosin was not associated with improvement in nightmares or sleep quality</td>
</tr>
<tr>
<td>Yesavage et al(^6) (2018)</td>
<td>Randomized trial in which 164 veterans with TRD were assigned to left prefrontal rTMS (treatment group) or sham rTMS (control group)</td>
<td>Overall, 40.7% of the treatment group and 37.4% of the control group achieved remission. The difference between the two groups was not significant</td>
</tr>
</tbody>
</table>

**Clinical Point**

Higher-dose antipsychotic use is associated with increased rates of unexpected death in children and young adults.

**Table**

Top psychiatric research findings of 2018-2019: Part 1

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ray et al(^1) (2019)</td>
<td>Large retrospective cohort study of children/young adults age 5 to 24 who received higher-dose antipsychotics (&gt;50 mg chlorpromazine equivalents; (n = 30,120)), lower-dose antipsychotics (≤50 mg chlorpromazine equivalents; (n = 28,377)), or control medications ((n = 189,361))</td>
<td>Compared with the control medication group, the incidence of death was significantly higher in the higher-dose antipsychotic group, but not in the lower-dose antipsychotic group</td>
</tr>
<tr>
<td>Daly et al(^2) (2019)</td>
<td>Double-blind, randomized study of 705 adults who received intranasal esketamine for TRD. Two hundred ninety-seven participants achieved remission or stable response and were randomized to receive continued esketamine nasal spray plus an oral antidepressant, or a placebo nasal spray plus an oral antidepressant</td>
<td>Continued esketamine nasal spray plus an oral antidepressant was associated with decreased rates of relapse compared with treatment with placebo nasal spray and an oral antidepressant</td>
</tr>
<tr>
<td>Williams et al(^3) (2018)</td>
<td>Double-blind crossover study in which 12 patients with TRD received placebo or naltrexone prior to an IV infusion of ketamine</td>
<td>Reductions in HAM-D scores among participants in the ketamine plus naltrexone group were significantly lower than those of participants in the ketamine plus placebo group</td>
</tr>
<tr>
<td>Nidich et al(^4) (2018)</td>
<td>Comparative effectiveness trial in which 203 veterans with PTSD were randomly assigned to receive TM, PE, or PTSD health education</td>
<td>Transcendental meditation was found to be significantly non-inferior to PE, with a mean change in CAPS score of -16.1 in the TM group and -11.2 in the PE group</td>
</tr>
<tr>
<td>Raskind et al(^5) (2018)</td>
<td>Double-blind controlled trial in which 304 veterans with PTSD nightmares were randomly assigned to prazosin or placebo</td>
<td>Compared with placebo, prazosin was not associated with improvement in nightmares or sleep quality</td>
</tr>
<tr>
<td>Yesavage et al(^6) (2018)</td>
<td>Randomized trial in which 164 veterans with TRD were assigned to left prefrontal rTMS (treatment group) or sham rTMS (control group)</td>
<td>Overall, 40.7% of the treatment group and 37.4% of the control group achieved remission. The difference between the two groups was not significant</td>
</tr>
</tbody>
</table>

**CAPS:** Clinician-Administered PTSD Scale; **HAM-D:** Hamilton Depression Rating Scale; **PE:** prolonged exposure therapy; **PTSD:** posttraumatic stress disorder; **rTMS:** repetitive transcranial magnetic stimulation; **TM:** transcendental meditation; **TRD:** treatment-resistant depression

Discuss this article at [www.facebook.com/MDedgePsychiatry](http://www.facebook.com/MDedgePsychiatry)
deficit/hyperactivity disorder medications, antidepressants, and mood stabilizers.

• There were 189,361 participants in the control group, 28,377 participants in the lower-dose antipsychotic group, and 30,120 participants in the higher-dose antipsychotic group.

Outcomes

• The primary outcome was death due to injury or suicide or unexpected death occurring during study follow-up.

• The incidence of death in the higher-dose antipsychotic group (146.2 per 100,000 person-years) was significantly higher ($P < .001$) than the incidence of death in the control medications group (54.5 per 100,000 person-years).

• There was no similar significant difference between the lower-dose antipsychotic group and the control medications group.

Conclusion

• Higher-dose antipsychotic use is associated with increased rates of unexpected deaths in children and young adults.

• As with all association studies, no direct line connected cause and effect. However, these results reinforce recommendations for careful prescribing and monitoring of antipsychotic regimens for children and youths, and the need for larger antipsychotic safety studies in this population.

• Examining risks associated with specific antipsychotics will require larger datasets, but will be critical for our understanding of the risks and benefits.


Controlled studies have shown esketamine has efficacy for treatment-resistant depression (TRD), but these studies have been only short-term, and the long-term effects of esketamine for TRD have not been established. To fill that gap, Daly et al assessed the efficacy of esketamine nasal spray plus an oral antidepressant vs a placebo nasal spray plus an oral antidepressant in delaying relapse of depressive symptoms in patients with TRD. All patients were in stable remission after an optimization course of esketamine nasal spray plus an oral antidepressant.

Study design

• Between October 2015 and February 2018, researchers conducted a phase III, multicenter, double-blind, randomized withdrawal study to evaluate the effect of continuation of esketamine on rates of relapse in patients with TRD who had responded to initial treatment with esketamine.

• Initially, 705 adults were enrolled. Of these participants, 455 proceeded to the optimization phase, in which they were treated with esketamine nasal spray plus an oral antidepressant.

• After 16 weeks of optimization treatment, 297 participants achieved remission or stable response and were randomized to a treatment group, which received continued esketamine nasal spray plus an oral antidepressant, or to a control group, which received a placebo nasal spray plus an oral antidepressant.

Outcomes

• Treatment with esketamine nasal spray and an oral antidepressant was associated with decreased rates of relapse compared with treatment with placebo nasal spray and an oral antidepressant. This was the case among patients who had achieved remission as well as those who had achieved stable response.

• Continued treatment with esketamine decreased the risk of relapse by 51%, with 40 participants in the treatment group experiencing relapse compared with 73 participants in the placebo group.

Conclusion

• In patients with TRD who responded to initial treatment with esketamine, continuing esketamine plus an oral antidepressant resulted in clinically meaningful superiority in preventing relapse compared with a placebo nasal spray plus an oral antidepressant.

Clinical Point

Continued treatment with esketamine plus an oral antidepressant decreased the risk of relapse to depression.

Many studies have documented the efficacy of ketamine as a rapid-onset antidepressant. Studies investigating the mechanism of this effect have focused on antagonism of N-methyl-D-aspartate (NMDA) receptors. However, several clinical trials that attempted to replicate this rapid antidepressant effect with other NMDA receptor antagonists had only limited success. Williams et al conducted the first human study that presents evidence that opioid receptor activation may be necessary for ketamine’s acute antidepressant effect.

**Study design**

- This double-blind crossover study evaluated if opioid receptor activation is necessary for ketamine to have an antidepressant effect in patients with TRD.
- Twelve participants completed both sides of the study in a randomized order. Participants received placebo or naltrexone prior to an IV infusion of ketamine.
- Researchers measured patients’ scores on the Hamilton Depression Rating Scale (HAM-D) at baseline and 1 day after infusion. Response was defined as a ≥50% reduction in HAM-D score.

**Outcomes**

- Reductions in HAM-D scores among participants in the ketamine plus naltrexone group were significantly lower than those of participants in the ketamine plus placebo group.
- Dissociation related to ketamine use did not differ significantly between the naltrexone group and the placebo group.

**Conclusion**

- This small study found a significant decrease in the antidepressant effect of ketamine infusion in patients with TRD when opioid receptors are blocked with naltrexone prior to infusion, which suggests opioid receptor activation is necessary for ketamine to be effective as an antidepressant.

- This appears to be consistent with observations of buprenorphine’s antidepressant effects. Caution is indicated until additional studies can further elucidate the mechanism of action of ketamine’s antidepressant effects (see “Ketamine/esketamine: Putative mechanism of action,” page 32).


Posttraumatic stress disorder (PTSD) is a common and important public health problem. Evidence-based treatments for PTSD include trauma-focused therapies such as prolonged exposure therapy (PE). However, some patients may not respond to PE, drop out, or elect not to pursue it. Researchers continue to explore treatments that are non-trauma-focused, such as mindfulness meditation and interpersonal psychotherapy. In a 3-group comparative effectiveness trial, Nidich et al examined the efficacy of a non-trauma-focused intervention, transcendental meditation (TM), in reducing PTSD symptom severity and depression in veterans.

**Study design**

- Researchers recruited 203 veterans with PTSD from the Department of Veterans Affairs (VA) San Diego Healthcare System between June 2013 and October 2016.
- Participants were randomly assigned to 1 of 3 groups: 68 to TM, 68 to PE, and 67 to PTSD health education (HE).
- Each group received 12 sessions over 12 weeks. In addition to group and individual sessions, all participants received daily practice or assignments.
- The Clinician-Administered PTSD Scale (CAPS) was used to assess symptoms before and after treatment.

**Outcomes**

- The primary outcome assessed was change in PTSD symptom severity at the end of the study compared with baseline as measured by change in CAPS score.
Transcendental meditation was found to be significantly non-inferior to PE, with a mean change in CAPS score of $-16.1$ in the TM group and $-11.2$ in the PE group.

Both the TM and PE groups also had significant reductions in CAPS scores compared with the HE group, which had a mean change in CAPS score of $-2.5$.

Conclusion

- Transcendental meditation is significantly not inferior to PE in the treatment of veterans with PTSD.
- The findings from this first comparative effectiveness trial comparing TM with an established psychotherapy for PTSD suggests the feasibility and efficacy of TM as an alternative therapy for veterans with PTSD.
- Because TM is self-administered after an initial expert training, it may offer an easy-to-implement approach that may be more accessible to veterans than other treatments.


Several smaller randomized trials of prazosin involving a total of 283 active-duty service members, veterans, and civilian participants have shown efficacy of prazosin for PTSD-related nightmares, sleep disturbance, and overall clinical functioning. However, in a recent trial, Raskind et al\(^5\) failed to demonstrate such efficacy.

Study design

- Veterans with chronic PTSD nightmares were recruited from 13 VA medical centers to participate in a 26-week, double-blind, randomized controlled trial.
  - A total of 304 participants were randomized to a prazosin treatment group ($n = 152$) or a placebo control group ($n = 152$).
  - During the first 10 weeks, prazosin or placebo were administered in an escalating fashion up to a maximum dose.
  - The CAPS, Pittsburgh Sleep Quality Index (PSQI), and Clinical Global Impressions of Change (CGIC) scores were measured at baseline, after 10 weeks, and after 26 weeks.

Outcomes

- Three primary outcomes measures were assessed: change in score from baseline to 10 weeks on CAPS item B2, the PSQI, and the CGIC.
  - A secondary measure was change in score from baseline of the same measures at 26 weeks.
  - There was no significant difference between the prazosin group and the placebo group in any of the primary or secondary measures.

Conclusion

- Compared with placebo, prazosin was not associated with improvement in nightmares or sleep quality for veterans with chronic PTSD nightmares.
  - Because psychosocial instability was an exclusion criterion, it is possible that a selection bias resulting from recruitment of patients who were mainly in clinically stable condition accounted for these negative results, since symptoms in such patients were less likely to be ameliorated with antiadrenergic treatment.


Treatment-resistant depression in veterans is a major clinical challenge because of these patients’ increased risk of suicide. Repetitive transcranial magnetic stimulation (rTMS) has shown promising results for TRD. In a randomized trial, Yesavage et al\(^6\) compared rTMS vs sham rTMS in veterans with TRD.

Study design

- Veterans with TRD were recruited from 9 VA medical centers throughout the United States between September 2012 and May 2016.
  - Researchers randomized 164 participants into 1 of 2 groups in a double-blind
The treatment group (n = 81) received left prefrontal rTMS, and the control group (n = 83) received sham rTMS.

### Outcomes

- In an intention-to-treat analysis, remission rate (defined as a HAM-D score of ≤10) was assessed as the primary outcome measure.
- Remission was seen in both groups, with 40.7% of the treatment group achieving remission and 37.4% of the control group achieving remission. However, the difference between the 2 groups was not significant ($P = .67$), with an odds ratio of 1.16.

### Conclusion

- In this study, treatment with rTMS did not show a statistically significant difference in rates of remission from TRD in veterans compared with sham rTMS. This differs from previous rTMS trials in non-veteran patients.
- The findings of this study also differed from those of other rTMS research in terms of the high remission rates that were seen in both the active and sham groups.

### References


### Bottom Line

The risk of death might be increased in children and young adults who receive high-dose antipsychotics. Continued treatment with intranasal esketamine may help prevent relapse in patients with treatment-resistant depression (TRD) who initially respond to esketamine. The antidepressant effects of ketamine might be associated with opioid receptor activation. Transcendental meditation may be helpful for patients with posttraumatic stress disorder (PTSD), while prazosin might not improve nightmares or sleep quality in patients with PTSD. Repetitive transcranial magnetic stimulation (rTMS) might not be any more effective than sham rTMS for veterans with TRD.